Significance of CD80 as a Prognostic and Immunotherapeutic Biomarker in Lung Adenocarcinoma.

Feng, Wei; He, Ziyi; Shi, Liang; Zhu, Zheng; Ma, Haitao

Feng, Wei; He, Ziyi; Shi, Liang; Zhu, Zheng; Ma, Haitao.

Afiliación

Feng W; First Affiliated Hospital of Soochow University, Suzhou, China.
He Z; First Affiliated Hospital of Soochow University, Suzhou, China.
Shi L; First Affiliated Hospital of Soochow University, Suzhou, China.
Zhu Z; First Affiliated Hospital of Soochow University, Suzhou, China.
Ma H; First Affiliated Hospital of Soochow University, Suzhou, China. mht7403@163.com.

Biochem Genet ; 61(5): 1937-1966, 2023 Oct.

Article en En | MEDLINE | ID: mdl-36892747

Asunto(s)

Adenocarcinoma del Pulmón; Neoplasias Pulmonares; Humanos; Pronóstico; Biomarcadores; Adenocarcinoma del Pulmón/tratamiento farmacológico; Adenocarcinoma del Pulmón/genética; Neoplasias Pulmonares/tratamiento farmacológico; Neoplasias Pulmonares/genética; Inmunoterapia

Palabras clave

CD80; Immune checkpoint inhibitors (ICIs); Immune response; Lung adenocarcinoma (LUAD); Prognosis; Small-molecule drugs

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Adenocarcinoma del Pulmón / Neoplasias Pulmonares Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Biochem Genet Año: 2023 Tipo del documento: Article País de afiliación: China

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google